Thoratec Announces Approval for HeartMate II in Japan
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that the company has received approval from Japan's Ministry of Health, Labour and Welfare to market HeartMate II® ^ as a Bridge-to-Transplantation therapy for patients suffering from advanced heart failure.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.